CMN Weekly (29 March 2024) - Your Weekly CRISPR...
CMN Weekly
Mar. 29, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Beam Therapeutics
General information
Main focus: Base editing for the treatment of genetic diseases and cancer
Company stage: Pre-clinical
Diseases: Sickle cell disease, beta-thalassemia, acute lymphoblastic leukaemia (ALL), alpha-1 antitrypsin deficiency, glycogen storage disorder-1, Stargardt disease
Genome-editing tool: Cytosine base editor, adesonine base editor, prime editing
Funding stage: Public (NASDAQ:BEAM)
Location: Cambridge, MA, USA
Website: https://beamtx.com/
Pipeline: https://beamtx.com/our-portfolio/
Partners: Prime Medicine, Verve Therapeutics, Sana Biotechnology, Apellis Pharmaceuticals, Bio Palette
Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists from the CRISPR field, Beam is pursuing therapies for serious diseases using its proprietary base-editing technology, which can make precise edits to single base pairs in DNA and RNA. The company's most advanced programme is in IND-enabling studies for sickle cell anaemia.
Tags
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
T-Cell Acute Lymphoblastic Leukaemia, T-ALL, and Lymphoma, T-LL, (NCT05885464)
Sponsors:
Beam Therapeutics Inc.
Sponsors:
Beam Therapeutics Inc.
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
